ERBB2 and breast cancer: Using a multi-omics approach to identify cytokines, transcription factors, kinases, and miRNAs or other secretory factors that CAFs release can aid in the identification of novel biomarkers that cause therapy resistance in HER2+ breast cancer and other forms of cancer.